Osteoporosi (anno 28°)
Raccolta bibliografica PubMed a cura di C.Tarozzi  (gennaio 2023)
Scelte bibliografiche compilate nel mese di gennaio 2023. Numero di lavori trovati 20
Kendler DL, Marin F, Zerbini CAF, Russo LA, Greenspan SL, Zikan V, Bagur A, Malouf-Sierra J, Lakatos P, Fahrleitner-Pammer A, Lespessailles E, Minisola S, Body JJ, Geusens P, Möricke R, López-Romero P.
Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial.
Lancet. 2018 Jan 20;391(10117):230-240.
Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH.
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
N Engl J Med. 2001 May 10;344(19):1434-41.
Leder BZ, Mitlak B, Hu MY, Hattersley G, Bockman RS.
Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis.
J Clin Endocrinol Metab. 2020 Mar 1;105(3):938-43.
Brown JP, Engelke K, Keaveny TM, Chines A, Chapurlat R, Foldes AJ, Nogues X, Civitelli R, De Villiers T, Massari F, Zerbini CAF, Wang Z, Oates MK, Recknor C, Libanati C.
Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the Active-Controlled Fracture Study in Postmenopausal Women With Osteoporosis at High Risk (ARCH) trial.
J Bone Miner Res. 2021 Nov;36(11):2139-2152.
Tsai JN, Lee H, David NL, Eastell R, Leder BZ.
Combination denosumab and high dose teriparatide for postmenopausal osteoporosis (DATA-HD): a randomised, controlled phase 4 trial.
Lancet Diabetes Endocrinol. 2019 Oct;7(10):767-775.
Reid IR, Billington EO.
Drug therapy for osteoporosis in older adults.
Lancet. 2022 Mar 12;399(10329):1080-1092.
McClung MR, Clark AL.
Osteoanabolic therapy for osteoporosis in women.
Climacteric. 2022 Feb;25(1):60-66.
Gregson CL, Armstrong DJ, Bowden J, Cooper C, Edwards J, Gittoes NJL, Harvey N, Kanis J, Leyland S, Low R, McCloskey E, Moss K, Parker J, Paskins Z, Poole K, Reid DM, Stone M, Thomson J, Vine N, Compston
UK clinical guideline for the prevention and treatment of osteoporosis.
J. Arch Osteoporos. 2022 Apr 5;17(1):58.
Bandeira L, Lewiecki EM.
Anabolic therapy for osteoporosis: update on efficacy and safety.
Arch Endocrinol Metab. 2022 Nov 11;66(5):707-716.
Rozenberg S, Vandromme J, Revercez P, Valcarenghi M, Joris A.
Menopause Hormone Therapy in the Management of Postmenopausal Osteoporosis.
Cancer J. 2022 May-Jun 01;28(3):204-207.
Kendler DL, Marin F, Zerbini CAF, Russo LA, Greenspan SL, Zikan V, Bagur A, Malouf-Sierra J, Lakatos P, Fahrleitner-Pammer A, Lespessailles E, Minisola S, Body JJ, Geusens P, Möricke R, López-Romero P.
Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial.
Lancet. 2018 Jan 20;391(10117):230-240.
Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH.
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
N Engl J Med. 2001 May 10;344(19):1434-41.
Leder BZ, Mitlak B, Hu MY, Hattersley G, Bockman RS.
Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis.
J Clin Endocrinol Metab. 2020 Mar 1;105(3):938-43.
Brown JP, Engelke K, Keaveny TM, Chines A, Chapurlat R, Foldes AJ, Nogues X, Civitelli R, De Villiers T, Massari F, Zerbini CAF, Wang Z, Oates MK, Recknor C, Libanati C.
Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the Active-Controlled Fracture Study in Postmenopausal Women With Osteoporosis at High Risk (ARCH) trial.
J Bone Miner Res. 2021 Nov;36(11):2139-2152.
Tsai JN, Lee H, David NL, Eastell R, Leder BZ.
Combination denosumab and high dose teriparatide for postmenopausal osteoporosis (DATA-HD): a randomised, controlled phase 4 trial.
Lancet Diabetes Endocrinol. 2019 Oct;7(10):767-775.
Reid IR, Billington EO.
Drug therapy for osteoporosis in older adults.
Lancet. 2022 Mar 12;399(10329):1080-1092.
McClung MR, Clark AL.
Osteoanabolic therapy for osteoporosis in women.
Climacteric. 2022 Feb;25(1):60-66.
Gregson CL, Armstrong DJ, Bowden J, Cooper C, Edwards J, Gittoes NJL, Harvey N, Kanis J, Leyland S, Low R, McCloskey E, Moss K, Parker J, Paskins Z, Poole K, Reid DM, Stone M, Thomson J, Vine N, Compston J.
UK clinical guideline for the prevention and treatment of osteoporosis.
Arch Osteoporos. 2022 Apr 5;17(1):58.
Bandeira L, Lewiecki EM.
Anabolic therapy for osteoporosis: update on efficacy and safety.
Arch Endocrinol Metab. 2022 Nov 11;66(5):707-716.
Rozenberg S, Vandromme J, Revercez P, Valcarenghi M, Joris A.
Menopause Hormone Therapy in the Management of Postmenopausal Osteoporosis.
Cancer J. 2022 May-Jun 01;28(3):204-207.
modificato in data 22-1-2023